Physician profile
Yuefeng Wang
NPI 1770994667
$2,770.69
in general payments reported to CMS, 2019-2025
12 companies · $44.49 in 2025
The $44.49 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $184 · 2021: $16.67 · 2022: $95.44 · 2023: $144 · 2024: $885 · 2025: $44.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Travel and Lodging: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.30 |
| Travel and Lodging | $473.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,592.22 | 2019-2025 | Optune Gio |
| Teleflex LLC | $803.45 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $121.53 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $65.34 | 2023-2024 | Imfinzi |
| Incyte Corporation | $57.12 | 2022 | |
| Siemens Medical Solutions USA, INC. | $36.52 | 2021-2024 | Varian Ethos Treatment Planning |
| Merck Sharp & Dohme LLC | $23.31 | 2025 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $18.42 | 2024 | Opdualag |
| Novartis Pharmaceuticals Corporation | $15.63 | 2022 | |
| Amgen INC. | $14.63 | 2022 | |
| Angiodynamics, INC. | $14.46 | 2019 | |
| Secura Bio, INC. | $8.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuefeng Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.